1. PRODUCT SUMMARY
GLP-1 / GIP / GCG agonist is an innovative experimental peptide characterized by its unique “triple agonist” mechanism, which targets GIP, GLP-1, and glucagon receptors simultaneously. This multi-pathway approach has generated significant scientific interest for its role in investigating metabolic signaling, glucose homeostasis, and lipid regulation.
2. STORAGE & STABILITY PROTOCOL
Lyophilized Powder: Store at -20°C (-4°F) for long-term stability. Protect from light and moisture.
Reconstituted Solution: Once liquid is added, the product must be kept refrigerated at 2–8°C (36–46°F).
Handling: Avoid repeated freeze-thaw cycles or vigorous agitation of the reconstituted solution.
3. RESEARCH OBJECTIVES & APPLICATIONS
This compound is intended for the following areas of laboratory study:
Synergistic Activation: Analyzing the effects of concurrent GLP-1, GIP, and glucagon receptor activation.
Metabolic Signaling: Evaluating mechanisms of energy homeostasis and systemic metabolic regulation.
Glycemic Studies: Investigating pathways involved in insulin sensitivity and glucose stability.
Lipid Modulation: Researching biological triggers for satiety signaling and adipose tissue reduction.
4. REGULATORY DISCLAIMER
WARNING: This product is supplied exclusively FOR ACADEMIC AND LABORATORY RESEARCH APPLICATIONS. It is STRICTLY NOT FOR HUMAN USE, nor is it intended for any clinical, therapeutic, medical, or diagnostic procedures. Use of this product must be conducted by qualified professionals in a controlled environment.
5. REFERENCES
- A Game Changer in Obesity Pharmacotherapy
https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/ - Triple Hormone Receptor Agonist for Metabolic Dysfunction–Associated Steatohepatitis
https://www.nature.com/articles/s41591-024-03018-2 - Effects on Body Composition in People with Type 2 Diabetes
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00092-0/fulltext - A Study of LY3437943 in Participants With Obesity or Overweight (NCT05929066)
https://clinicaltrials.gov/study/NCT05929066 - A Study of LY3437943on Cardiovascular Outcomes (NCT06383390)
https://clinicaltrials.gov/study/NCT06383390 - A Study of LY3437943 in Participants With Obesity and Cardiovascular Disease (NCT05882045)
https://clinicaltrials.gov/study/NCT05882045 - LY3437943, a Triple GIP/GLP-1/Glucagon Receptor Agonist: Preclinical Characterization
https://pubmed.ncbi.nlm.nih.gov/35658025/
Reviews
There are no reviews yet.